Mode
Text Size
Log in / Sign up
N/A N=144 Randomized Single-blind Treatment

Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

Depression

Enrolled (actual)
144
Serious AEs
11.1%
Results posted
Dec 2014
Primary outcome: Primary: Time to Remission — 13.67; 11.33 weeks

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fluoxetine (Drug); Relapse prevention cognitive behavioral therapy (CBT) (Behavioral)
Age
Pediatric · 8+ yrs
Sex
All
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Feb 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Remission
13.67; 11.33
PRIMARY
Relapse
49; 27; 62; 36
PRIMARY
Remission
59; 68; 71; 79; 80; 86
SECONDARY
K-Life (Time Well)
12.8; 16.0 .02 sig
SECONDARY
Remission
59; 68; 71; 79; 80; 86
SECONDARY
Relapse
49; 27; 62; 36

Summary

This study will compare the effectiveness of fluoxetine alone with the effectiveness of fluoxetine with cognitive behavioral therapy in increasing recovery and preventing relapse in youth with major depressive disorder.

Eligibility Criteria

Inclusion Criteria

  • Primary diagnosis of nonpsychotic MDD (single or recurrent) for at least 4 weeks before study entry
  • In good general medical health
  • Normal intelligence

Exclusion Criteria

  • Lifetime history of any psychotic disorder, including psychotic depression
  • Lifetime history of bipolar I and II disorders
  • Alcohol or substance dependence within the 6 months before study entry
  • Anorexia nervosa or bulimia within the 6 months before study entry
  • Pregnant or breastfeeding females, or sexually active females not using medically acceptable means of birth control (e.g., IUD, birth control pills, barrier devices)
  • Chronic medical illness (medically unstable and requires regular medication that may interfere with treatment interventions)
  • Concurrent medication(s) with psychotropic effects (e.g., anticonvulsants, steroids, etc.) other than stable ADHD medication
  • First degree relatives with bipolar I disorder
  • Severe suicidal ideation or previous history of serious suicide attempt within this episode
  • Prior failure to respond to an adequate treatment with fluoxetine (defined as at least 40 mg/day for 4 weeks)
  • Non-English speaking
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00612313). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search